GLYPALCARE STUDY - Multicenter, Randomized Study for Evaluating Continuous Glucose Monitoring (CGM) by Using FreeStyle Libre 2 (FSL2) for Preventing Hyperglycemia/Hypoglycemia Crisis in Advanced Oncological Patients.
GLYPALCARE STUDY - Multicenter, Randomized Study for Evaluating Continuous Glucose Monitoring (CGM) by Using FreeStyle Libre 2 (FSL2) for Preventing Hyperglycemia/Hypoglycemia Crisis in Advanced Oncological Patients With Known/Newly Diagnosed Type I/Type II Diabetes Mellitus (DM) in Palliative Care/ Supportive Care (PC/SC) Setting.
Sponsor: Abbott Diabetes Care
A NA clinical study on Advanced Cancer and Cancer, this trial is ongoing. The trial is conducted by Abbott Diabetes Care and has accumulated 4 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Aug 2023 — Jul 2024 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Sep 2021 — Aug 2023 [monthly]
Active Not Recruiting NA
First recorded
Jun 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott Diabetes Care
- Antea Foundation
For direct contact, visit the study record on ClinicalTrials.gov .